Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report)’s share price crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $45.54 and traded as high as $48.57. Scholar Rock shares last traded at $48.00, with a volume of 2,774,436 shares trading hands.
Analyst Ratings Changes
Several equities research analysts have weighed in on the company. Wolfe Research cut Scholar Rock from an “outperform” rating to a “peer perform” rating in a research note on Thursday, November 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price target on shares of Scholar Rock in a research report on Monday, September 21st. BMO Capital Markets increased their target price on shares of Scholar Rock from $76.00 to $84.00 and gave the company an “outperform” rating in a research note on Monday, September 14th. Barclays lowered shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a report on Tuesday, September 15th. Finally, Wedbush reiterated an “outperform” rating and set a $64.00 price target on shares of Scholar Rock in a report on Tuesday, September 15th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $69.50.
View Our Latest Stock Report on Scholar Rock
Scholar Rock Stock Performance
The firm has a market cap of $5.86 billion, a price-to-earnings ratio of -14.29 and a beta of 0.78. The company has a debt-to-equity ratio of 1.16, a current ratio of 5.41 and a quick ratio of 5.40. The firm has a fifty day simple moving average of $45.54 and a two-hundred day simple moving average of $48.24.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the previous year, the firm posted ($0.90) EPS. On average, analysts expect that Scholar Rock Holding Corporation will post -3.04 EPS for the current year.
Insider Buying and Selling
In other Scholar Rock news, Director Srinivas Akkaraju bought 146,970 shares of the firm’s stock in a transaction dated Monday, October 26th. The shares were purchased at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares of the company’s stock, valued at approximately $265,365,702.03. This represents a 2.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.30% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in SRRK. Allworth Financial LP acquired a new position in Scholar Rock in the 2nd quarter valued at about $35,000. PNC Financial Services Group Inc. increased its stake in Scholar Rock by 92.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company’s stock worth $62,000 after acquiring an additional 610 shares during the last quarter. IFP Advisors Inc raised its position in Scholar Rock by 219.0% in the third quarter. IFP Advisors Inc now owns 1,560 shares of the company’s stock valued at $75,000 after purchasing an additional 1,071 shares during the period. GAMMA Investing LLC raised its position in Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock valued at $77,000 after purchasing an additional 242 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in Scholar Rock in the second quarter valued at about $99,000. 91.08% of the stock is owned by institutional investors and hedge funds.
Scholar Rock Company Profile
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.
Featured Articles
- Five stocks we like better than Scholar Rock
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
